Cyclerion

Cyclerion

Biotechnology, Cambridge, Massachusetts, 02142, United States, 1-10 Employees

cyclerion.com

  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is CYCLERION

Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that ...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from CYCLERION

Cyclerion Org Chart and Mapping

Employees

Carol Lincoln

Director Total Rewards and Operations

Cheryl Gault

Chief Operating Officer

Ying Shu

Sr. Scientist, Analytical Development

Hossein Razavi

Senior Principal Investigator

Sokol Malollari

Sr. Director, Corporate Controller

Mason Yeh

Associate Director, New Product Planning & Corporate Strategy

Bill Kissel

Sr. Director, Chemical Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Cyclerion

Answer: Cyclerion's headquarters are located at Cambridge, Massachusetts, 02142, United States

Answer: Cyclerion's phone number is 61********

Answer: Cyclerion's official website is https://cyclerion.com

Answer: Cyclerion's revenue is $25 Million to $50 Million

Answer: Cyclerion's SIC: 2834

Answer: Cyclerion has 1-10 employees

Answer: Cyclerion is in Biotechnology

Answer: Cyclerion contact info: Phone number: 61******** Website: https://cyclerion.com

Answer: Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access